Three lawsuits filed by patients alleging they suffered kidney damage and heart disease from Johnson & Johnson’s type 2 diabetes drug Invokana have been filed in federal court in New Jersey.
The lawsuits name Johnson & Johnson, its subsidiary Janssen Pharmaceuticals, and Mitsubishi Tanabe Pharma Corp., the company that developed Invokana, as defendants.
One of the lawsuits was filed on behalf of South Carolina resident Cornelius Benjamin. It claims Benjamin began taking Invokana to treat his diabetes in April 2013. He suffered a stroke and kidney damage, and died two months after beginning treatment with Invokana.
Another lawsuit, filed by Robert Partington of Alabama, claims the plaintiff suffered kidney damage 19 months after taking Invokana. The third lawsuit, filed by Texas resident Maria Puente, claims she suffered kidney damage and diabetic ketoacidosis after taking Invokana.
All lawsuits claim that the drug companies failed to warn patients of potential side effects with Invokana and fraudulently and intentionally concealed the drug’s side effects from users. Similar Invokana side effects lawsuits are pending in federal court in Alabama, the Court of Common Pleas in Philadelphia, and Ontario, Canada.
Invokana was approved by the Food and Drug Administration (FDA) in 2013 for the treatment of type 2 diabetes. The drug had sales of $278 million in the first quarter of 2015.
An analysis of adverse events reported to the FDA shows that patients taking Invokana are at an increased risk of developing kidney disease compared to other types of diabetes treatments. In May 2015, the FDA warned that Invokana had been linked to a serious condition called ketoacidosis, in which too much acid builds up in the blood. If left untreated, ketoacidosis can lead to diabetic coma and death.
Source: NJ Law Journal